SuperworthFulgent Genetics profit margin FLGT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −26.0%
- Operating margin, 12 months
- −37.7%
- Net margin on a year earlier
- −9.2 pts
- Peer median
- 9.5%
Over the twelve months to Jun 30, 2026, Fulgent Genetics kept −26.0% of its revenue as net profit, with an operating margin of −37.7% and a gross margin of 35.6%.
Five years earlier its net margin was 54.2%.
The median for 5 diagnostics and research stocks of a similar size is 9.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −18.8% | −28.2% | 40.6% |
| FY2024 | −15.1% | −26.1% | 37.8% |
| FY2023 | −58.0% | −67.6% | 36.1% |
| FY2022 | 23.2% | 28.8% | 59.3% |
| FY2021 | 51.1% | 68.1% | 78.3% |
| FY2020 | 50.8% | 68.8% | 78.7% |
| FY2019 | −1.3% | −1.3% | 56.6% |
| FY2018 | −26.3% | −23.7% | 49.9% |
| FY2017 | −13.4% | −18.6% | 54.3% |
| FY2016 | −29.3% | 5.0% | 63.2% |
| FY2015 | n/a | −52.3% | 47.1% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −26.0% | −9.2 pts | −37.7% | |
| Q1 FY26 | −23.0% | −9.1 pts | −33.1% | |
| Q4 FY25 | −18.8% | −3.7 pts | −28.2% | |
| Q3 FY25 | −13.6% | +45.8 pts | −22.5% | |
| Q2 FY25 | −16.8% | +39.4 pts | −24.0% | |
| Q1 FY25 | −13.9% | +43.8 pts | −24.6% | |
| Q4 FY24 | −15.1% | +43.0 pts | −26.1% | |
| Q3 FY24 | −59.4% | −37.2 pts | −75.2% | |
| Q2 FY24 | −56.2% | −40.4 pts | −65.9% | |
| Q1 FY24 | −57.7% | −50.6 pts | −67.0% | |
| Q4 FY23 | −58.0% | −81.2 pts | −67.6% | |
| Q3 FY23 | −22.2% | −56.0 pts | −28.3% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Fulgent Genetics' size, closest first, today.
| Company | Profit margin |
|---|---|
| FLGTFulgent Genetics | −26.0% |
| NRCNRC Health | 4.2% |
| ICCCImmucell | 2.6% |
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| Peer median | 9.5% |
Where Fulgent Genetics ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Fulgent Genetics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.